FIELD: pharmaceutics.
SUBSTANCE: invention refers to pharmaceutical industry, namely to a method of treating SARS-CoV-2. Method of treating SARS-CoV-2, comprising using: Ingavirin 90 mg once day for 7 days, Amoksiklav 875 mg + 125 mg 2 times day for 7 days, Acetylcysteine 600 mg once day for 7 days, characterized by the fact that a therapeutic composition containing succinic acid and taurine is additionally administered orally in dosage unit 4 times day for 7 days, with the following ratio of components in one dosage unit, g: succinic acid – 1.0, taurine – 0.75.
EFFECT: use of the invention provides the formation of long-term antiviral resistance, which is necessary and sufficient for the rapid and effective elimination of the pathogen virus and the elimination of the symptoms of SARS-CoV-2, as well as more effective and fast effect, which patients immediately feel on 2-3 days of treatment.
1 cl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| 2-(IMIDAZOL-4-YL)-ETHANAMIDE OF PENTANEDIOIC ACID OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING COVID-19 AND SYMPTOMS THEREOF | 2021 |
|
RU2824607C2 |
| METHOD FOR PREVENTION OR TREATMENT OF CORONAVIRUS AND OTHER ACUTE RESPIRATORY VIRAL INFECTIONS | 2022 |
|
RU2794315C1 |
| MEFLOQUINE AND COMBINATIONS THEREOF FOR TREATING AND PREVENTING A CORONAVIRUS INFECTION | 2020 |
|
RU2763024C1 |
| METHOD FOR COMPLEX THERAPY OF PEDIATRIC PATIENTS WITH VIRAL INFECTION USING PROBIOTIC FOOD PRODUCTS | 2021 |
|
RU2793833C1 |
| METHOD FOR COVID-19 PNEUMONIA TREATMENT | 2020 |
|
RU2745535C1 |
| METHODS FOR TREATING INFECTIOUS DISEASES CAUSED BY CORONAVIRUS | 2021 |
|
RU2772701C1 |
| METHOD FOR PROTECTION AGAINST CORONAVIRUS INFECTION | 2020 |
|
RU2747467C1 |
| METHOD OF TREATING COVID-19 IN CHILDREN AT RISK OF SEVERE CLINICAL COURSE OF DISEASE | 2023 |
|
RU2815303C1 |
| METHOD FOR CORONAVIRUS INFECTION TREATMENT | 2021 |
|
RU2751488C1 |
| PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OF VIRAL DISEASES | 2021 |
|
RU2780252C1 |
